TORONTO, September 16, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia approved the settlement of a class action lawsuit filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder and underwriters (the “Canadian Settlement”). Canadian Settlement Considers CDN Cash Payment $1.9 millionof which the Company will pay CDN $1.6 million.

Braxia Scientific Corp logo. (CNW Group/Braxia Scientific Corp.) (CNW Group/Braxia Scientific Corp.)

Court approval of a tentative agreement (the “U.S. Settlement”) to settle claims alleged in a securities class action lawsuit (the “U.S. Class Action”) against the Company and certain of its former officers filed in United States District Court of the Central District of California in April 2021, remains pending. The U.S. Settlement contemplates a cash payment by the Company of USD $1 million to settle the US class action lawsuit.

Once insurance is available, and assuming U.S. settlement court approval is obtained, the total cost to the Company to settle both class actions will be approximately CDN $1.36 million.

About Braxia Scientific Corp.

Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for people with depression and related disorders. Braxia has also launched its US-based end-to-end telemedicine platform, KetaMD, which uses cutting-edge technology to provide access to safe, affordable and potentially life-changing at-home ketamine treatments. people with depression and related mental health issues. Through its medical solutions, Braxia aims to reduce the disease burden of brain disorders, such as major depressive disorder, among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing in-person and virtual treatment for mental health disorders, and (ii) research activities related to the discovery and commercialization of new drugs and methods of administration. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly-owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community clinics offering fast-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawaand Montreal.


“dr. Roger S. McIntyre
dr. Roger S. McIntyre


The CSE has not reviewed and accepts no responsibility for the accuracy or adequacy of this release.

Forward-looking information Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs about future performance are “forward-looking statements”.

Forward-looking statements include statements about the expected promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine, psilocybin, and other psychedelics to provide expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals , including acquiring and renewing federal, state, municipal, local or other licenses and engaging in activities that may subsequently be deemed illegal under national or international law. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and possession of such substances under the CDSA without a prescription or legal exemption is a criminal offence. Health Canada has not approved psilocybin as a drug for any indication, but ketamine is a legally authorized drug for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without prescription.

These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other risk factors that cause the actions, events or results differ from those anticipated, estimated or expected. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available at There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in the forward-looking statements.



View original content for multimedia download:

SOURCE Braxia Scientific Corp.



View original content to download multimedia: